Clinical trial
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)
NCT02946879 is registered in ClinicalTrials.gov with MeiraGTx UK II Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)
- Lead sponsor
- MeiraGTx UK II Ltd
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 30, 2016
- Completion date
- July 31, 2023
- Enrollment
- 15 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
eye diseases, eye diseases, hereditary, leber congenital amaurosis (lca), retinal diseases